Key facts
- This page summarizes Mubadala Investment Co PJSC's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2023, 15:09.
Mubadala Investment Co PJSC - 02 Mar 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- RXRX
- Reported as of
- 02 Mar 2023
- Net transaction value
- +$522,354
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2023, 15:09:13 UTC
- Prior SEC filing
- 02 Mar 2023
- Next SEC filing
- 09 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Samer Halawa, Chief Legal Officer, Mubadala Investment Company PJSC (6)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mubadala Investment Co PJSC filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 03 Mar 2023.
Change
- Previous filing in this sequence was filed on 02 Mar 2023.
- Current net transaction value: +$522,354.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Purchase
- Transaction value
- $522,354
- Shares
- +66,822
- Change %
- +0.52%
- Price
- $7.82
- Shares after
- 12,985,927
- Date
- 02 Mar 2023
- Ownership
- See Explanation of Responses
- Footnotes
- F1, F2, F4, F5
RXRX
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,062,869
- Date
- 02 Mar 2023
- Ownership
- See Explanation of Responses
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4.
Footnote F2
Consists of 12,985,927 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.
Footnote F3
MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
Footnote F4
Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
Footnote F5
Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
SEC remarks
6. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.